MedTrace Logo

Dietary Habits, Metabolome, Immune Profile and Microbiota in Patients With Bone Sarcoma

NCT04735289 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 810

Last updated 2023-08-04

No results posted yet for this study

Summary

Osteosarcoma and Ewing sarcoma treatment has not changed in the last 30 years.

For other types of cancer the epidemiologic and prognostic correlations between dietary behavior, lifestyle and metabolic alterations (i.e.obesity, insulin-resistance) are well known (breast cancer, prostate cancer, colon cancer). However, no epidemiological or prognostic data are available about the metabolic profile and lifestyle behaviors in patients with osteosarcoma and Ewing'sarcoma and only few preclinical studies are available. An in vitro study showed a higher glucose and glutamine consumption from metastatic osteosarcoma cells compared to primary tumor osteosarcoma cells. The effect of the intestinal microbiota into the metabolism of nutrients, drugs, inflammation, epigenetic and immune response was found not only correlated to gastrointestinal tumors but also to other tumors outside gastrointestinal system as well The aim of this study is to investigate if there are differential dietary habits, metabolome, microbiota or immune profile in patients with bone sarcoma compared to a control population in a 1:2 multicenter study.

Conditions

Interventions

OTHER

EPIC-COS Food Frequency Questionnaire diet Evaluation

Anthropometric measurements (Body mass Index, Lean and fat body composition evaluation) and diet habits evaluation with EPIC-COS-FFQ

OTHER

Metabolome, Microbiota, Lymphocytes subpopulations

At diagnosis before any treatment for bone sarcoma will be obtained : 1. a blood sample for metabolomics analyses 2. a stool sample for microbiota analysis 3. Lymphocyte subpopulations (CD3, CD4, CD8, NK) will be analyzed in blood samples

Sponsors & Collaborators

  • International Agency for Research on Cancer

    collaborator OTHER

  • Istituto Ortopedico Rizzoli

    lead OTHER

Principal Investigators

  • Alessandra Longhi, MD · Istituto Ortopedico Rizzoli - Bologna

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-03-10
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04735289 on ClinicalTrials.gov